Lupin is hoping to turn the corner in the US, led by key approvals of generic versions of Renexa and Synthroid in place and a possible launch of Albuterol MDI in second half of FY20.
Subscribe to:
Post Comments (Atom)
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
-
The BRLLR linked to RBI Repo Rate is revised downwards in line with the reduction on Reserve Bank of India Repo Rate from 5.15 percent to 4...
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
No comments:
Post a Comment